Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Tekmira Changes Name to Arbutus Biopharma | Contract Pharma

What are you searching for?

Sign in
Breaking News

Tekmira Changes Name to Arbutus Biopharma

Suspends work on Ebola, will focus on Hepatitis B drug development

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Tekmira Pharmaceuticals Corporation revealed plans to halt its work on TKM-Ebola and change its corporate name to Arbutus Biopharma Corporation. Arbutus will focus on developing a cure for chronic hepatitis B virus infection (HBV). The name change affirms the integration of OnCore BioPharma and Tekmira Pharmaceuticals into a combined company with the goal of delivering a cure for chronic HBV. The combined entity fields the largest portfolio of HBV product candidates in the industry.

Tekmira has also formed a business unit for Tekmira’s non-HBV assets that includes preclinical RNAi product candidates, IP and related know how of the lipid nanoparticle (LNP) delivery technology platform, and multiple strategic partnerships exploiting the LNP technology. The company said development activities related to TKM-Ebola will be suspended and a joint re-evaluation of the development contract with the U.S. Department of Defense is underway.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics